8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 17, 2026·SEC
Mainz Biomed B.V.(MYNZ)Earnings, Financials & Key Ratios
MYNZ•NASDAQ
Price updated Jun 20, 2026
AboutMainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Show more
- Revenue$894K-0.2%
- EBITDA-$18M+31.0%
- Net Income-$22M+17.7%
- EPS (Diluted)-22.36-1280.2%
- Gross Margin64.31%+13.0%
- EBITDA Margin-1977.47%+30.9%
- Operating Margin-2091.23%+29.7%
- Net Margin-2421.8%+17.5%
- ROE-465.82%-53.6%
MYNZ Key Insights
Mainz Biomed B.V. (MYNZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Strong 5Y sales CAGR of 26.0%
- ✓Share count reduced 94.0% through buybacks
- ✓Trading near 52-week high
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Profits declining 86.6% over 5 years
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MYNZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MYNZ Price & Volume
Mainz Biomed B.V. (MYNZ) stock price & volume — 10-year historical chart
Loading chart...
MYNZ Growth Metrics
Mainz Biomed B.V. (MYNZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years26.01%
3 Years15.69%
TTM45.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1156.11%
Return on Capital
10 Years-331.67%
5 Years-326.05%
3 Years-244.12%
Last Year-277.78%
MYNZ Peer Comparison
Mainz Biomed B.V. (MYNZ) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 GKOS | 8.06B | 137.76 | -42 | 32.33% | -34.34% | -26.46% | 0.21 | |
 NTRA | 37.23B | 259.97 | -171.03 | 35.9% | -9.05% | -15.13% | 0.13 | |
 SDGR | 1.15B | 15.35 | -10.88 | 23.29% | -40.6% | -30.85% | 0.30 | |
 GH | 18.16B | 136.96 | -41.25 | 32.88% | -40.1% | |||
 ILMN | 26.6B | 175.09 | 32.13 | -0.78% | 19.43% | 32.84% | 0.94 | |
 CERS | 528.97M | 2.64 | -32.20 | 14.35% | -4.41% | -15.18% | 1.49 | |
 TMO | 182.91B | 492.20 | 27.75 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare MYNZ vs Peers
Mainz Biomed B.V. (MYNZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MYNZ Income Statement
Mainz Biomed B.V. (MYNZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
Sales/Revenue | 281.39K | 493.56K | 577.35K | 529.88K | 895.48K | 893.99K |
Revenue Growth % | - | 75.4% | 16.98% | -8.22% | 69% | -0.17% |
Cost of Goods Sold | 342.66K | 370.48K | 399.73K | 347.73K | 385.82K | 319.11K |
COGS % of Revenue | 121.77% | 75.06% | 69.23% | 65.62% | 43.09% | 35.69% |
Gross Profit | -61.27K▲ 0% | 123.08K▲ 300.9% | 177.62K▲ 44.3% | 182.15K▲ 2.5% | 509.66K▲ 179.8% | 574.88K▲ 12.8% |
Gross Margin % | -21.77% | 24.94% | 30.77% | 34.38% | 56.91% | 64.31% |
Gross Profit Growth % | - | 300.89% | 44.31% | 2.55% | 179.8% | 12.8% |
Operating Expenses | 690.21K | 796.8K | 9.56M | 26.36M | 27.15M | 19.27M |
OpEx % of Revenue | 245.28% | 161.44% | 1655.31% | 4974.16% | 3032.38% | 2155.54% |
Selling, General & Admin | 570.25K | 458.37K | 9.41M | 22.81M | 17.22M | 12.77M |
SG&A % of Revenue | 202.65% | 92.87% | 1630.05% | 4304.86% | 1923.17% | 1428.98% |
Research & Development | 250.32K | 311.85K | 466.69K | 3.66M | 9.59M | 5.84M |
R&D % of Revenue | 88.96% | 63.18% | 80.83% | 690.82% | 1070.98% | 653.14% |
Other Operating Expenses | -130.35K | 26.57K | -320.89K | -114.05K | 342.4K | 656.34K |
Operating Income | -921.91K▲ 0% | -766.09K▲ 16.9% | -9.72M▼ 1169.4% | -26.44M▼ 171.9% | -26.64M▼ 0.8% | -18.7M▲ 29.8% |
Operating Margin % | -327.62% | -155.22% | -1684.36% | -4990.6% | -2975.47% | -2091.23% |
Operating Income Growth % | - | 16.9% | -1169.38% | -171.93% | -0.76% | 29.83% |
EBITDA | -868.87K | -613.25K | -9.65M | -25.98M | -25.61M | -17.68M |
EBITDA Margin % | -308.77% | -124.25% | -1672.25% | -4903.9% | -2859.94% | -1977.47% |
EBITDA Growth % | - | 29.42% | -1474.34% | -169.14% | 1.44% | 30.97% |
D&A (Non-Cash Add-back) | 53.04K | 152.84K | 69.93K | 459.43K | 1.03M | 1.02M |
EBIT | -755.12K | -410.48K | -11.35M | -26.1M | -26.05M | -20.58M |
Net Interest Income | -201.94K | -268.79K | -339.17K | -289.32K | -809.58K | -1.08M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 201.94K | 268.79K | 339.17K | 289.32K | 809.58K | 1.08M |
Other Income/Expense | -35.15K | 86.82K | -1.97M | 56.7K | 348.95K | -2.96M |
Pretax Income | -957.05K▲ 0% | -586.89K▲ 38.7% | -11.7M▼ 1892.7% | -26.39M▼ 125.6% | -26.3M▲ 0.3% | -21.65M▲ 17.7% |
Pretax Margin % | -340.11% | -118.91% | -2025.67% | -4979.9% | -2936.5% | -2421.8% |
Income Tax | 0 | 0 | 377.12K | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | -3.22% | 0% | 0% | 0% |
Net Income | -957.05K▲ 0% | -586.89K▲ 38.7% | -11.69M▼ 1891.9% | -26.45M▼ 126.3% | -26.3M▲ 0.6% | -21.65M▲ 17.7% |
Net Margin % | -340.11% | -118.91% | -2024.79% | -4992.24% | -2936.5% | -2421.8% |
Net Income Growth % | - | 38.68% | -1891.86% | -126.28% | 0.59% | 17.66% |
Net Income (Continuing) | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.10▲ 0% | -0.05▲ 49.9% | -1.67▼ 3233.3% | -1.87▼ 12.0% | -1.62▲ 13.4% | -22.36▼ 1280.2% |
EPS Growth % | - | 49.9% | -3233.33% | -11.98% | 13.37% | -1280.25% |
EPS (Basic) | -0.10 | -0.05 | -1.67 | -1.87 | -1.62 | -22.36 |
Diluted Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
Basic Shares Outstanding | 11.71M | 5.61M | 7.21M | 14.16M | 16.24M | 968.23K |
Dividend Payout Ratio | - | - | - | - | - | - |
MYNZ Balance Sheet
Mainz Biomed B.V. (MYNZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
Total Current Assets | 260.01K | 186.4K | 9.61M | 18.38M | 8.98M | 7.84M |
Cash & Short-Term Investments | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
Cash Only | 203.59K | 122.57K | 8.73M | 17.14M | 7.07M | 6.24M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 40.8K | 44.24K | 17.76K | 259.14K | 354.51K | 213.75K |
Days Sales Outstanding | 52.92 | 32.72 | 11.23 | 178.5 | 144.5 | 87.27 |
Inventory | 0 | 0 | 0 | 175.47K | 613.64K | 372.87K |
Days Inventory Outstanding | - | - | - | 184.19 | 580.52 | 426.49 |
Other Current Assets | 0 | 0 | 0 | 0 | 135.06K | 127.29K |
Total Non-Current Assets | 455.95K | 486.87K | 431.59K | 1.86M | 6.43M | 5.39M |
Property, Plant & Equipment | 455.95K | 486.87K | 431.59K | 1.84M | 3.03M | 2.38M |
Fixed Asset Turnover | 0.62x | 1.01x | 1.34x | 0.29x | 0.30x | 0.38x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 3.39M | 3.02M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 23.27K | 108 | 0 |
Total Assets | 715.96K▲ 0% | 673.27K▼ 6.0% | 10.04M▲ 1391.3% | 20.24M▲ 101.6% | 15.41M▼ 23.9% | 13.24M▼ 14.1% |
Asset Turnover | 0.39x | 0.73x | 0.06x | 0.03x | 0.06x | 0.07x |
Asset Growth % | - | -5.96% | 1391.35% | 101.59% | -23.87% | -14.09% |
Total Current Liabilities | 459.71K | 701.95K | 1.35M | 4.24M | 9.24M | 5.95M |
Accounts Payable | 200.06K | 195.41K | 832.52K | 1.33M | 2.33M | 1.25M |
Days Payables Outstanding | 213.1 | 192.52 | 760.19 | 1.4K | 2.2K | 1.43K |
Short-Term Debt | 173.66K | 219.02K | 193.43K | 1.04M | 4.94M | 2.13M |
Deferred Revenue (Current) | 2.5K | 1.51K | 0 | 199.41K | 138.89K | 0 |
Other Current Liabilities | 0 | 98.16K | -3.22K | 0 | 388.84K | 690.58K |
Current Ratio | 0.57x | 0.27x | 7.11x | 4.33x | 0.97x | 1.32x |
Quick Ratio | 0.57x | 0.27x | 7.11x | 4.29x | 0.91x | 1.26x |
Cash Conversion Cycle | - | - | - | -1.04K | -1.48K | -920.79 |
Total Non-Current Liabilities | 2.21M | 2.71M | 2.33M | 1.9M | 2.92M | 1.24M |
Long-Term Debt | 1.79M | 2.27M | 1.94M | 943.21K | 1.03M | 0 |
Capital Lease Obligations | 418.14K | 447.44K | 387.77K | 959.12K | 1.17M | 865.98K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 726.98K | 376.1K |
Total Liabilities | 2.67M | 3.41M | 3.68M | 6.14M | 12.16M | 7.19M |
Total Debt | 2.41M | 2.98M | 2.58M | 3.23M | 7.42M | 3.27M |
Net Debt | 2.21M | 2.86M | -6.15M | -13.91M | 349.86K | -2.96M |
Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
Debt / EBITDA | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - |
Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
Total Equity | -1.95M▲ 0% | -2.74M▼ 40.6% | 6.36M▲ 332.0% | 14.1M▲ 121.6% | 3.25M▼ 76.9% | 6.05M▲ 86.1% |
Equity Growth % | - | -40.57% | 332.03% | 121.6% | -76.95% | 86.09% |
Book Value per Share | -0.17 | -0.49 | 0.88 | 1.00 | 0.20 | 6.24 |
Total Shareholders' Equity | -1.95M | -2.74M | 6.36M | 14.1M | 3.25M | 6.05M |
Common Stock | 106.11K | 64.27K | 141.07K | 164.9K | 235.82K | 922.13K |
Retained Earnings | -4.37M | -4.95M | -16.64M | -43.03M | -69.33M | -90.98M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 2.31M | 2.11M | 9.74M | 18.13M | 20.83M | 27.04M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
MYNZ Cash Flow Statement
Mainz Biomed B.V. (MYNZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|
Cash from Operations | -416.5K | -468.74K | -3.22M | -14.77M | -21.94M | -17.09M |
Operating CF Margin % | -148.01% | -94.97% | -557.78% | -2787.36% | -2449.96% | -1911.65% |
Operating CF Growth % | - | -12.54% | -587.02% | -358.64% | -48.54% | 22.1% |
Net Income | -957.05K | -586.89K | -11.69M | -26.39M | -26.3M | -21.65M |
Depreciation & Amortization | 53.04K | 60.46K | 69.93K | 379.8K | 866.41K | 1.02M |
Stock-Based Compensation | 0 | 0 | 6.43M | 9.82M | 4.01M | 1.14M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 64.48K | 107 | 2.11M | 1.85M | -450.53K | 2.36M |
Working Capital Changes | 423.04K | 57.59K | -138.62K | -437.4K | -64.63K | 51.75K |
Change in Receivables | 339.62K | -99.15K | 24.21K | -211.23K | 15.54K | 64.28K |
Change in Inventory | 0 | -160.48K | -670.73M | -172.38K | -500.19K | 29.81K |
Change in Payables | 0 | 160.48K | 670.73M | 0 | 720.24K | 84.61K |
Cash from Investing | 0 | -9.69K | 1.2M | -658.48K | -1.9M | -198.82K |
Capital Expenditures | 0 | -9.69K | -16.7K | -658.48K | -1.2M | -104.95K |
CapEx % of Revenue | - | 1.96% | 2.89% | 124.27% | 133.88% | 11.74% |
Acquisitions | 0 | 0 | 1.22M | 0 | 0 | 32.78K |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -700K | -126.65K |
Cash from Financing | 424K | 396.68K | 10.61M | 23.94M | 14.23M | 16.6M |
Debt Issued (Net) | 424K | -2.13K | 185.37K | -197.94K | 7.83M | 2.83M |
Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 398.81K | 0 | -107.03K | 0 | 0 |
Net Change in Cash | -25.94K▲ 0% | -81.02K▼ 212.3% | 8.6M▲ 10720.8% | 8.41M▼ 2.2% | -10.07M▼ 219.7% | -835.25K▲ 91.7% |
Free Cash Flow | -416.5K▲ 0% | -478.42K▼ 14.9% | -3.24M▼ 576.6% | -15.43M▼ 376.6% | -23.84M▼ 54.5% | -17.34M▲ 27.2% |
FCF Margin % | -148.01% | -96.93% | -560.67% | -2911.63% | -2662% | -1940.17% |
FCF Growth % | - | -14.87% | -576.61% | -376.61% | -54.51% | 27.24% |
FCF per Share | -0.04 | -0.09 | -0.45 | -1.09 | -1.47 | -17.91 |
FCF Conversion (FCF/Net Income) | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
Interest Paid | 0 | 0 | 0 | 125.54K | 0 | 198.06K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
MYNZ Key Ratios
Mainz Biomed B.V. (MYNZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -645.93% | -258.62% | -303.2% | -465.82% |
Return on Invested Capital (ROIC) | - | -306.19% | -4482.93% | -10104.56% | -1056.87% | -419.72% |
Gross Margin | -21.77% | 24.94% | 30.77% | 34.38% | 56.91% | 64.31% |
Net Margin | -340.11% | -118.91% | -2024.79% | -4992.24% | -2936.5% | -2421.8% |
Debt / Equity | - | - | 0.41x | 0.23x | 2.28x | 0.54x |
Interest Coverage | -4.57x | -2.85x | -28.67x | -91.40x | -32.91x | -17.39x |
FCF Conversion | 0.44x | 0.80x | 0.28x | 0.56x | 0.83x | 0.79x |
Revenue Growth | - | 75.4% | 16.98% | -8.22% | 69% | -0.17% |
Related:MYNZ Dividend History·MYNZ Revenue History·MYNZ Price History·MYNZ P/E History·MYNZ Financial Ratios·MYNZ Institutional Holders
MYNZ SEC Filings & Documents
Mainz Biomed B.V. (MYNZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-K Annual Reports
1FY 2026
Mar 31, 2026·SEC
MYNZ Frequently Asked Questions
Mainz Biomed B.V. (MYNZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mainz Biomed B.V. (MYNZ) reported $1.6M in revenue for fiscal year 2024. This represents a 472% increase from $0.3M in 2019.
Mainz Biomed B.V. (MYNZ) saw revenue decline by 0.2% over the past year.
Mainz Biomed B.V. (MYNZ) reported a net loss of $40.1M for fiscal year 2024.
Dividend & Returns
Mainz Biomed B.V. (MYNZ) has a return on equity (ROE) of -465.8%. Negative ROE indicates the company is unprofitable.
Mainz Biomed B.V. (MYNZ) had negative free cash flow of $27.5M in fiscal year 2024, likely due to heavy capital investments.